Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 315

1.

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Kwiatkowski DJ, Manning BD.

Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. Review.

PMID:
16244323
[PubMed - indexed for MEDLINE]
Free Article
2.

Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.

Kwiatkowski DJ.

Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6. Review.

PMID:
14614311
[PubMed - indexed for MEDLINE]
Free Article
3.

Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.

Li Y, Inoki K, Guan KL.

Mol Cell Biol. 2004 Sep;24(18):7965-75.

PMID:
15340059
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.

Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J.

Curr Biol. 2003 Aug 5;13(15):1259-68.

PMID:
12906785
[PubMed - indexed for MEDLINE]
5.

Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.

Astrinidis A, Henske EP.

Oncogene. 2005 Nov 14;24(50):7475-81. Review.

PMID:
16288294
[PubMed - indexed for MEDLINE]
6.

The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.

Nobukini T, Thomas G.

Novartis Found Symp. 2004;262:148-54; discussion 154-9, 265-8. Review.

PMID:
15562827
[PubMed - indexed for MEDLINE]
7.

Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.

Robb VA, Astrinidis A, Henske EP.

Mod Pathol. 2006 Jun;19(6):839-46. Erratum in: Mod Pathol. 2006 Jun;19(6):889.

PMID:
16575396
[PubMed - indexed for MEDLINE]
Free Article
8.

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.

Shah OJ, Wang Z, Hunter T.

Curr Biol. 2004 Sep 21;14(18):1650-6.

PMID:
15380067
[PubMed - indexed for MEDLINE]
9.

TSC2: filling the GAP in the mTOR signaling pathway.

Li Y, Corradetti MN, Inoki K, Guan KL.

Trends Biochem Sci. 2004 Jan;29(1):32-8. Review.

PMID:
14729330
[PubMed - indexed for MEDLINE]
10.

The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.

Smith EM, Finn SG, Tee AR, Browne GJ, Proud CG.

J Biol Chem. 2005 May 13;280(19):18717-27. Epub 2005 Mar 16.

PMID:
15772076
[PubMed - indexed for MEDLINE]
Free Article
11.

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL.

Genes Chromosomes Cancer. 2005 Mar;42(3):213-27.

PMID:
15578690
[PubMed - indexed for MEDLINE]
12.

Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway.

Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M.

Neuromolecular Med. 2005;7(4):287-96. Review.

PMID:
16391386
[PubMed - indexed for MEDLINE]
13.

The tuberous sclerosis complex genes in tumor development.

Mak BC, Yeung RS.

Cancer Invest. 2004;22(4):588-603. Review.

PMID:
15565817
[PubMed - indexed for MEDLINE]
14.

Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase.

Avruch J, Hara K, Lin Y, Liu M, Long X, Ortiz-Vega S, Yonezawa K.

Oncogene. 2006 Oct 16;25(48):6361-72. Review.

PMID:
17041622
[PubMed - indexed for MEDLINE]
15.

Measurements of TSC2 GAP activity toward Rheb.

Li Y, Inoki K, Vikis H, Guan KL.

Methods Enzymol. 2006;407:46-54.

PMID:
16757313
[PubMed - indexed for MEDLINE]
16.

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.

J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42.

PMID:
15624760
[PubMed - indexed for MEDLINE]
17.

Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin.

El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ.

Cancer Res. 2003 Sep 1;63(17):5173-7.

PMID:
14500340
[PubMed - indexed for MEDLINE]
Free Article
18.

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.

Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, Vazquez F, Carpenter CL, Kwiatkowski DJ.

J Clin Invest. 2003 Oct;112(8):1223-33.

PMID:
14561707
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R.

J Cell Biol. 2002 Oct 28;159(2):217-24. Epub 2002 Oct 28.

PMID:
12403809
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.

Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, Kozma SC, Hafen E, Bos JL, Thomas G.

Mol Cell. 2003 Jun;11(6):1457-66.

PMID:
12820960
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk